Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-4889
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR ; volume:13 ; number:7 ; day:12 ; month:7 ; year:2022 ; pages:1-14 ; date:7.2022
Cell death & disease ; 13, Heft 7 (12.7.2022), 1-14, 7.2022
- Urheber
-
Lee, Boah
Park, Seung Ju
Lee, Seulgi
Lee, Jinwook
Lee, Eunbeol
Yoo, Eun-Seon
Chung, Won-Suk
Sohn, Jong-Woo
Oh, Byung-Chul
Kim, Seyun
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41419-022-05039-6
- URN
-
urn:nbn:de:101:1-2022092715130799507563
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lee, Boah
- Park, Seung Ju
- Lee, Seulgi
- Lee, Jinwook
- Lee, Eunbeol
- Yoo, Eun-Seon
- Chung, Won-Suk
- Sohn, Jong-Woo
- Oh, Byung-Chul
- Kim, Seyun
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cholesterol-Lowering Super juice
Cholesterol lowering: role in cancer prevention and treatment
Low-density lipoprotein cholesterol lowering treatment: the current approach
mTOR inhibitors: A novel class of anti-cancer agents
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
Cholesterol-stabilized membrane-active nanopores with anticancer activities
Cyclic fasting bolsters cholesterol biosynthesis inhibitors’ anticancer activity
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Cholesterol-Lowering Super juice
Cholesterol lowering: role in cancer prevention and treatment
Low-density lipoprotein cholesterol lowering treatment: the current approach
mTOR inhibitors: A novel class of anti-cancer agents
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
Cholesterol-stabilized membrane-active nanopores with anticancer activities
Cyclic fasting bolsters cholesterol biosynthesis inhibitors’ anticancer activity
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Cholesterol-Lowering Super juice
Cholesterol lowering: role in cancer prevention and treatment
Low-density lipoprotein cholesterol lowering treatment: the current approach
mTOR inhibitors: A novel class of anti-cancer agents
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
Cholesterol-stabilized membrane-active nanopores with anticancer activities
Cyclic fasting bolsters cholesterol biosynthesis inhibitors’ anticancer activity
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis